Business Context and Reporting Period
Company: Moderna, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: March 3, 2026
Event: Entry into a Material Definitive Agreement (Settlement Agreement) with Arbutus Biopharma Corporation and Genevant Sciences GmbH to resolve all pending worldwide patent infringement litigation regarding Moderna's infectious disease portfolio, including Spikevax and mRESVIA.
Key Financial Metrics and Obligations
This filing details specific settlement payments rather than standard operating financial metrics (revenue, profit, cash flow). The filing text does not provide current revenue, profit, or liquidity figures.
- Noncontingent Payment: $950 million lump sum due on or before July 8, 2026.
- Contingent Payment: Up to $1.3 billion, payable within 90 days of a specific Federal Circuit decision regarding 28 U.S.C. § 1498.
- Maximum Potential Liability: $2.25 billion ($950 million + $1.3 billion).
- Repayment Provision: If the contingent payment is made and subsequently overturned in Moderna's favor, Arbutus/Genevant must return the payment plus interest.
Material Changes and Agreement Terms
The settlement resolves all litigation related to Moderna's full infectious disease portfolio, including mNEXSPIKE and mCOMBRIAX, with no future royalties owed. Key terms include:
- License Grant: Arbutus/Genevant grants Moderna a fully paid-up, royalty-free, irrevocable, non-exclusive, worldwide license to make, sell, and exploit vaccines using SM-102-based lipid nanoparticle (LNP) formulations.
- Appeal Rights: Moderna retains the right to appeal the District Court's rejection of its affirmative defense under 28 U.S.C. § 1498 to the Federal Circuit regarding doses sold to the U.S. Government.
- Contingency Trigger: The $1.3 billion payment is triggered if the Federal Circuit affirms the rejection of Moderna's defense or if Moderna fails to timely file or voluntarily dismisses the appeal.
- Proration: If the Federal Circuit determines § 1498 bars claims for only some doses, the $1.3 billion payment will be prorated based on the number of affected doses.
Guidance, Outlook, and Risks
Management Commentary: The agreement provides certainty for Moderna's infectious disease portfolio and future vaccine pipeline by eliminating future royalty obligations and resolving global litigation.
Risks and Contingencies:
- Legal Outcome Risk: The final financial impact depends on the Federal Circuit's ruling on the § 1498 defense. If Moderna prevails, no further payments beyond the $950 million are due.
- Cash Flow Impact: The company faces a significant near-term cash outflow of $950 million by July 2026, with potential additional outflows of up to $1.3 billion depending on litigation outcomes.
- Forward-Looking Statements: The filing includes standard disclaimers that actual results may differ materially from expectations due to risks described in the 2025 Form 10-K.
Investor Verification Checklist
- Verify the company's current cash and cash equivalents to assess the ability to fund the $950 million noncontingent payment by July 2026.
- Review the status of the appeal to the Federal Circuit regarding 28 U.S.C. § 1498 to gauge the probability of the $1.3 billion contingent payment.
- Confirm the specific number of vaccine doses sold to the U.S. Government that are subject to the § 1498 defense to understand potential proration scenarios.
- Monitor the upcoming Form 10-Q for the quarter ending March 31, 2026, for the full text of the Settlement Agreement and any updated financial impact analysis.
